Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
|Articles|October 18, 2021
Pharmacy Clinical Pearl of the Day: Aortic Valve Stenosis
Author(s)Saro Arakelians, PharmD
Causes of aortic valve stenosis include congenital heart defect, calcium build-up on the valve, and rheumatic fever.
Advertisement
Clinical Pearl of the Day: Aortic Valve Stenosis
Aortic valve stenosis—or aortic stenosis—occurs when the heart's aortic valve narrows.
Insight:
- Aortic valve stenosis causes the valve not to open fully, which reduces or blocks blood flow from the heart into the main artery (aorta) and to the rest of the body.
- Signs and symptoms include abnormal heart sound, chest pain, feeling faint or dizzy, shortness of breath, fatigue, rapid fluttering heartbeat, not eating enough, and not gaining weight.
- Causes of aortic valve stenosis include congenital heart defect, calcium build-up on the valve, and rheumatic fever.
- Risk factors include older age, certain heart conditions present at birth, history of infections, chronic kidney disease, history of radiation therapy to the chest.
- Treatment options include aortic valve repair, balloon valvuloplasty, aortic valve replacement, transcatheter aortic valve replacement.
Sources:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5